You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《美股業績》糖尿病藥物需求強勁 禮來上季盈收均勝預期
阿思達克 11-02 00:06
美國最大藥廠禮來(LLY.US)公布,受惠對糖尿病藥物Mounjaro強勁需求,第三季虧損5,740萬美元,每股虧損6美仙,不計入一次性項目,調整後每股盈利10美仙,較預期每股虧損13美仙表現好。去年同期利潤為14.5億美元,每股盈利1.61美元。 營收按年升37%至95億美元,高於預期的89.5億美元。 禮來稅前研發費用為29.8億美元,主要與最近一系列收購有關,包括收購Dice Therapeutics、Versanis Bio和Emergence Therapeutics。2022年第三季的費用為6,240萬美元。 由於主要與最近收購相關的費用,禮來大幅削減全年利潤指引,將2023年調整後每股收益指引從先前的每股9.7美元至9.9美元下調至6.5美元至6.7美元。重申全年營收預期在334億美元至339億美元之間。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account